Tejnaksh Healthcare Ltd Upgraded to Sell on Technical and Valuation Improvements

Technical Trends Shift to Sideways

The primary catalyst behind the upgrade is the change in the technical grade, which has moved from mildly bearish to sideways. This shift is supported by a mixed but cautiously optimistic set of technical indicators. On a weekly basis, the Moving Average Convergence Divergence (MACD) is mildly bullish, signalling potential momentum building, while the monthly MACD also remains mildly bullish. The Relative Strength Index (RSI) on both weekly and monthly charts shows no definitive signal, indicating a neutral momentum without overbought or oversold conditions.

Bollinger Bands present a bullish stance on the weekly chart, suggesting price stability with potential upside, though the monthly bands remain mildly bearish, reflecting some longer-term caution. Daily moving averages still trend mildly bearish, indicating short-term pressure, but the weekly and monthly Dow Theory assessments are mildly bullish, reinforcing the sideways technical outlook.

Other technical tools such as the Know Sure Thing (KST) indicator show a mildly bullish weekly reading but a bearish monthly trend, highlighting a divergence between short-term optimism and longer-term caution. Overall, these mixed signals have led to a more balanced technical grade, moving away from outright bearishness.

Valuation Grade Improves to Attractive

Alongside technical improvements, Tejnaksh Healthcare’s valuation grade has been upgraded from very attractive to attractive. The company currently trades at a price-to-earnings (PE) ratio of 24.29, which is reasonable compared to peers such as Suraksha Diagnostics (PE 44.73) and KMC Speciality (PE 39.14). Its enterprise value to EBITDA (EV/EBITDA) ratio stands at 11.73, also favourable relative to competitors.

The price-to-book value ratio of 1.26 further supports the attractive valuation thesis, indicating the stock is trading close to its book value, which is appealing for value investors. Return on capital employed (ROCE) and return on equity (ROE) are modest at 8.28% and 6.34% respectively, reflecting moderate profitability but still better than some peers with higher valuations.

Despite the upgrade, the valuation remains cautious given the company’s micro-cap status and the healthcare services sector’s competitive pressures. However, the improved valuation grade signals that the stock is no longer deeply undervalued but offers a fair entry point relative to its fundamentals and sector peers.

Financial Trend Remains Weak

Despite the positive technical and valuation shifts, Tejnaksh Healthcare’s financial trend continues to disappoint. The company reported flat financial performance in the third quarter of FY25-26, with no significant growth in operating profits. Over the last five years, operating profits have declined at a compound annual growth rate (CAGR) of -5.68%, signalling deteriorating operational efficiency.

Return on equity averaged 9.52% over this period, indicating low profitability relative to shareholders’ funds. The company’s debtor turnover ratio is notably low at 4.87 times for the half-year, suggesting inefficiencies in receivables management. Profitability has also been under pressure, with profits falling by 41.2% over the past year.

These weak financial trends have contributed to the stock’s underperformance against benchmarks. Tejnaksh Healthcare has generated a negative return of -29.85% over the last year, significantly lagging the Sensex, which declined by only -2.41% in the same period. Over three and five years, the stock’s returns have been -55.69% and -50.51% respectively, while the Sensex posted gains of 27.46% and 57.94% over those intervals.

Quality Parameters Still Lagging

The company’s quality metrics remain a concern. Despite the upgrade in technical and valuation grades, the overall Mojo Score stands at 34.0, with a Mojo Grade of Sell, improved from a previous Strong Sell. This reflects persistent weaknesses in fundamental quality, including low profitability and operational inefficiencies.

Tejnaksh Healthcare’s micro-cap status adds to the risk profile, as smaller companies often face greater volatility and liquidity challenges. Promoters remain the majority shareholders, which can be a stabilising factor, but the company’s consistent underperformance relative to peers and benchmarks tempers optimism.

Stock Price and Market Performance

Tejnaksh Healthcare’s stock price closed at ₹15.96 on 27 April 2026, up 2.90% from the previous close of ₹15.51. The stock’s 52-week high is ₹24.77, while the low is ₹12.10, indicating a wide trading range and significant volatility. Today’s trading range was between ₹15.65 and ₹16.49, reflecting moderate intraday movement.

Short-term returns have been mixed, with a one-week gain of 3.64% outperforming the Sensex’s decline of -1.55%. Over one month, the stock surged 42.75%, far exceeding the Sensex’s 5.06% gain. However, year-to-date returns are modest at 6.47%, while the Sensex is down -9.29%. Longer-term returns remain negative, underscoring the company’s ongoing challenges.

Outlook and Investor Considerations

While the upgrade to Sell from Strong Sell reflects some improvement in technical and valuation parameters, investors should remain cautious given the company’s weak financial trends and quality metrics. The sideways technical trend suggests a potential stabilisation in price action, but the lack of strong financial growth and profitability limits upside potential.

Valuation appears fair relative to peers, but the micro-cap status and historical underperformance warrant a conservative approach. Investors seeking exposure to the healthcare services sector may find better opportunities among companies with stronger fundamentals and more consistent earnings growth.

In summary, Tejnaksh Healthcare Ltd’s rating upgrade is driven primarily by a more balanced technical outlook and improved valuation grade, while financial and quality factors continue to weigh on the stock’s prospects. The Sell rating reflects a cautious stance, recognising some positive signals but acknowledging persistent risks.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →